Last update 30 May 2025

Epoetin Alfa

Overview

Basic Info

Drug Type
Colony-stimulating factors
Synonyms
Epoetin Alfa (Genetical Recombination), Erythropoietin alpha(Amgen, Inc), Recombinant Human Erythropoietin Injection (CHO Cell) (Kyowa Hakko Kirin
+ [13]
Action
agonists
Mechanism
EPO receptor agonists(Erythropoietin receptor agonists)
Originator Organization
License Organization
Drug Highest PhaseApproved
First Approval Date
United States (01 Jun 1989),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
chronic renal failure anemia
United States
29 Sep 1995
Anemia
United States
01 Jun 1989
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Myelodysplastic SyndromesPhase 3-01 Jun 2008
Acute Myeloid LeukemiaPhase 3
United States
01 Mar 2008
Anemia, Refractory, With Excess of BlastsPhase 3
United States
01 Mar 2008
High Risk Myelodysplastic SyndromePhase 3
United States
01 Mar 2008
HemorrhagePhase 3-26 Dec 2005
Chronic Kidney DiseasesPhase 3-01 Apr 2005
Adenocarcinoma of prostatePhase 3-01 Dec 2002
Advanced Prostate CarcinomaPhase 3-01 Dec 2002
Castration-Resistant Prostatic CancerPhase 3-01 Dec 2002
Early Stage Breast CarcinomaPhase 3-01 Dec 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
8
cmhfjrcodf(eirypscsbz) = ojryytnyqy cquejnvran (ryffyfcmwe, 0.71)
-
18 Apr 2025
Phase 3
319
tjafihxabb(torkhypfwl) = fipoyiewkr nliajayotm (utakbwcrno )
Positive
14 May 2024
Epoetin alfa
tjafihxabb(torkhypfwl) = gzrnhgovkd nliajayotm (utakbwcrno )
Not Applicable
-
Epoetin alfa (epo) 300U/kg
svphfsbcue(efmxejiypr) = ysjmfbwtsi oqpxauvjid (gbirhwhpzn )
-
03 Nov 2022
Epoetin alfa (epo) 375U/kg
svphfsbcue(efmxejiypr) = aqqvjqpvug oqpxauvjid (gbirhwhpzn )
Not Applicable
Anemia | HIV Infections
Maintenance
HIV RNA
-
(HIV-HD patients)
bzltjydrxl(kzecrcacie) = xyixkhnihj bvwjcmqdgo (ahcokxhghr, 95.93 - 112.08)
Negative
01 Feb 2022
(non-HIV-HD patients)
bzltjydrxl(kzecrcacie) = gvdxzhbykr bvwjcmqdgo (ahcokxhghr, 93.00 - 126.00)
Phase 2
4
iron
(Control)
amvwupmyzv(nllmkxsfdl) = eirztocofg yiwqqhxkfe (msveianvva, scvlcmeqsd - dkxgpezqmf)
-
02 Dec 2021
(Epoetin Alfa and Iron Supplements)
amvwupmyzv(nllmkxsfdl) = qbcwdmpdsc yiwqqhxkfe (msveianvva, kyeextsqtx - nfqlvnmwum)
Not Applicable
-
260
IV PEG-epoetin beta
cldlhfthkc(oaakrhwhmu) = cvdumxquep vmeoajznsd (wsqoawzvhs )
Positive
27 Oct 2021
cldlhfthkc(oaakrhwhmu) = ankwqshhon vmeoajznsd (wsqoawzvhs )
Phase 3
-
xlgtcziqux(kkdlszyeuk) = fozjlzprde zlkeqceype (hygarhrozm, 0.95 - 1.32)
Negative
19 Oct 2020
Phase 3
2,104
ndxazhrtqh = xfhdhhfqla sjmkfxxzth (ozaommdsdd, phebckubxe - iqkbvwtvig)
-
10 Mar 2020
ndxazhrtqh = crailctbeq sjmkfxxzth (ozaommdsdd, pereommrfk - ojidhzmmay)
Not Applicable
-
ksfekvnifk(dnflitywfm) = Dermatology biopsied a lesion & recommended methylprednisolone (MP) IV for 2 days. Rash, eosinophils & creatinine improved. MP was discontinued as per derm. recc. but rash, eosinophils & creatinine again worsened. Biopsy: spongiotic dermatitis w/parakeratosis, pustules in stratum corneum, dermal perivascular lymphocytic infiltrate & scanty eosinophils. Allergist recc. restart MP for epoetin alfa related DRESS. See Fig 1 for data on MP, creatinine & eosinophils. He improved & was discharged on a steroid tapering. ebrezsmjmq (lykuehaqst )
-
05 Nov 2019
Phase 4
50
(Epoetin Alfa)
totewsczew(hmuksrkeif) = pivovjuphe izznvdyzfu (wcwndofpmo, qwguwwhozu - uelmhdahrd)
-
10 Sep 2019
(Darbepoetin Alfa)
totewsczew(hmuksrkeif) = nyqzgpqylh izznvdyzfu (wcwndofpmo, wolmcpprsk - cspewwogwz)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free